In a significant setback for the UK government’s efforts to attract private sector investments, AstraZeneca has announced the cancellation of its proposed £450 million vaccine manufacturing plant at its Speke site, near Liverpool. The decision follows ongoing frustrations with the government’s handling of the investment process, as reported by The Times UK.
AstraZeneca, Britain’s largest public company, confirmed that after months of “protracted discussions” with the government, it would no longer pursue the investment. A spokesperson for the pharmaceutical giant cited multiple factors influencing the decision, including delays in securing government support and a reduction in the final offer compared to previous proposals. The company’s internal timeline was disrupted, and the final offer came much later than expected, despite private warnings that the issue was urgent.
The UK government’s handling of the matter drew heavy criticism from within AstraZeneca. The company had warned the Business Secretary, Jonathan Reynolds, that without early assurances on government support for the proposed plant, it would struggle to meet crucial internal deadlines. As reported in The Times, despite AstraZeneca’s urgency, the company did not receive those assurances in a timely manner. The final offer of support came only after Labour’s budget announcement in late October, which resulted in further delays.
The move is seen as a blow to Chancellor Rachel Reeves’ recent efforts to stimulate economic growth and attract investors to the UK. During a speech earlier this week, she had highlighted AstraZeneca as a key example of the government’s commitment to private sector growth. The proposed £450 million investment was initially announced in March as part of Jeremy Hunt’s budget in the last Conservative administration, alongside a £200 million expansion of AstraZeneca’s global research and development headquarters in Cambridge.
Despite the setback, AstraZeneca emphasized that its Speke site would continue to produce and supply flu vaccines for both the UK and international markets. The decision also underscores the challenges facing the UK’s vaccine manufacturing capability, an issue previously highlighted by former health secretary Matt Hancock. He warned earlier this month that strengthening the UK’s domestic vaccine production capacity was critical for preparing for future pandemics.
AstraZeneca’s decision follows a similar shift in its investment strategy. In 2023, CEO Sir Pascal Soriot expressed dissatisfaction with the UK’s fiscal environment, particularly its tax rates, which led to the company’s decision to build a $360 million manufacturing plant in Ireland instead. The company has also recently made large investments in the US and Canada.
